Track Olema Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Olema Pharmaceuticals, Inc. OLMA · Stock Open Olema Pharmaceuticals, Inc. in new tab

7.56 USD
EPS
-2.40
P/B
1.82
ROE
-69.77
Beta
2.02
Target Price
35.50 USD
Loading chart...
Key Metrics
Earnings dateMarch 23, 2027
EPS-2.40
Book Value4.21
Price to Book1.82
Debt/Equity0.91
% Insiders1.762%
Estimates
Forward P/E-2.64
Forward EPS-2.90
Target Mean Price35.50

DCF valuation

Model fair value for Olema Pharmaceuticals, Inc. (OLMA)
Result
Sign in to run the valuation for OLMA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 35.50 USD (low 13.00, high 59.00) · as of 12 Nov 2026
Low 13.00
Mean 35.50
High 59.00
Price 7.56
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Olema Pharmaceuticals, Inc. Logo Olema Pharmaceuticals, Inc. Analysis (OLMA)

United States Health Care Official Website Stock

Is Olema Pharmaceuticals, Inc. a good investment? Olema Pharmaceuticals, Inc. (OLMA) is currently trading at 7.56 USD. Market analysts have a consensus price target of 35.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Olema Pharmaceuticals, Inc. is expected to release its next earnings report on March 23, 2027. The market consensus estimate for Forward EPS is -2.90.

Investor FAQ

Does Olema Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Olema Pharmaceuticals, Inc.?

Olema Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 23, 2027. The company currently has a trailing EPS of -2.40.

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Exchange Ticker
NMS (United States) OLMA
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion